Barbara Blond, MBA, MT(ASCP)
All laboratories that are using molecular methods to test human papillomavirus, or HPV, are required by CLIA ’88 to have a license for testing and to participate in annual proficiency testing for HPV. Laboratories that do molecular testing for HPV but do not participate in a general virology proficiency test are required to participate annually in three events consisting of five challenges each.
The CAP offers a new human papillomavirus Survey for 2008, CHPV, that meets the CLIA requirement for a three-event/five-samples-per-event program. It is the only proficiency test available in the United States that is specific to type of transport/preservative media. The purpose of this Survey is to determine presence or absence of high-risk HPV. The HPV samples are unique since the participant is required to take the samples through preanalytic, analytic, and postanalytic steps. This enables laboratories that use cell lysis as part of their procedure to test this step. Testing all phases ensures the accuracy and reliability of test results.
There are four different modules of CHPV to allow users to choose the sample type(s) received in their laboratory.
The CHPV Survey material is compatible with Digene Hybrid Capture technology and Third Wave Technologies Invader reagents. The first CHPV Survey will be mailed on March 31. Contact the CAP at 800-323-4040 to enroll in the CHPV Survey
Barbara Blond is manager of CAP Surveys.